Akari Therapeutics Plc, an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, has entered a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program AKTX-101 is initially targeting metastatic urothelial cancer, where there continues to be significant unmet medical need particularly in the second-line treatment se...